Opthea’s Promising Results in Diabetic Macular Edema Trial Published

An announcement from Opthea Limited ( (AU:OPT) ) is now available.

Opthea Limited announced the publication of its Phase 1b trial results for sozinibercept, a novel VEGF-C/D ‘trap’ therapy, in the journal Translational Vision Science & Technology. The study, which involved patients with persistent diabetic macular edema (DME), demonstrated that sozinibercept combined with aflibercept was well-tolerated and improved visual acuity and anatomical outcomes, supporting its potential as a new treatment for DME. With DME being a leading cause of vision loss in diabetics and its prevalence set to rise, these findings could have significant implications for patient care and Opthea’s positioning in the ophthalmology market.

More about Opthea Limited

Opthea Limited is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for the treatment of prevalent and progressive retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is being assessed in pivotal Phase 3 clinical trials to enhance the efficacy of standard anti-VEGF-A therapies.

YTD Price Performance: 0%

Average Trading Volume: 17,450

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $586.6M

For a thorough assessment of OPT stock, go to TipRanks’ Stock Analysis page.